Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
RPG Life Sciences Ltd

| Standalone Audited Financial Results for the Quarter and Year Ended March 31, 2026

Report Source

⬤29th Apr 26

Summary : RPG Life Sciences reports strong FY26 results, declares dividend, and undertakes strategic restructuring.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Cost of Materials Consumed (Standalone FY26): 13,598 Lakhs.
  2. Employee Benefits Expense (Standalone FY26): 14,148 Lakhs.
  3. Other Expenses (Standalone FY26): 16,682 Lakhs.
  4. Revenue from Operations (Standalone FY26): 70,752 Lakhs.
  5. Revenue from Operations (Consolidated FY26): 70,752 Lakhs.
  6. Net cash inflow from operating activities (Standalone FY26): 5,650 Lakhs.
  7. Net cash inflow from investing activities (Standalone FY26): 5,106 Lakhs.
  8. Net cash outflow from financing activities (Standalone FY26): (2,058) Lakhs.
  9. Cash and cash equivalents at year end (Standalone FY26): 11,568 Lakhs.
  10. Total Assets (Standalone FY26): 79,314 Lakhs.
  11. Total Equity (Standalone FY26): 60,537 Lakhs.
  12. Total Liabilities (Standalone FY26): 18,777 Lakhs.
  13. Transfer of API division to wholly owned subsidiary, RPG Active Pharma Limited.
  14. Both standalone and consolidated financial results are presented and audited.

Corporate Overview

  1. Impact of new Labour Codes on employee benefits.
  2. Fire incident at API plant caused losses.
  3. Operates in the Pharmaceuticals segment.
  4. Pharmaceuticals

Risk Factors

  1. Uncertainty from new labor codes.
  2. Past fire incident impact on operations.
  3. Intangible asset impairment write-off.
  4. Regulatory approvals for API division transfer.

Key Drivers

  1. Strong financial performance, profit growth.
  2. Significant dividend declared for shareholders.
  3. Strategic API division transfer to WOS.
  4. New independent director appointed.

Auditor’s Report

  1. Unmodified opinion on standalone and consolidated financial results.

Board Commentary

  1. Appointment of Dr. Pratit Samdani as Additional Non-Executive Independent Director for 5 years.
  2. Recommended dividend of Rs. 24/- (300%) per equity share for FY 2025-26.
  3. Amendment to Code of fair disclosure and insider trading regulations.
  4. Compliance with SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
  5. Approved transfer of API division to wholly owned subsidiary, RPG Active Pharma Limited.

Corporate Governance

  1. Amendment to Code of fair disclosure and insider trading.
  2. Appointment of an Additional Non-Executive Independent Director.
  3. Nomination and Remuneration Committee.
  4. Audit Committee.

Management Discussion & Analysis

Future Strategy

  1. Transfer of API division to wholly owned subsidiary.

Performance Drivers

  1. Increased revenue from operations.
  2. Effective management of exceptional items.

Risk Control Measures

  1. Monitoring finalisation of Central State Rules for Labour Codes.

Critical Risks

  1. Regulatory changes from new Labour Codes.
  2. Potential delays in API division transfer approvals.
RPG Life Sciences Ltd (RPGLIFE) Quarterly Report Analysis & Insights | Dhanarthi